HK1256087A1 - 用於實體瘤靶向的雙特異性cart細胞 - Google Patents
用於實體瘤靶向的雙特異性cart細胞Info
- Publication number
- HK1256087A1 HK1256087A1 HK18115149.8A HK18115149A HK1256087A1 HK 1256087 A1 HK1256087 A1 HK 1256087A1 HK 18115149 A HK18115149 A HK 18115149A HK 1256087 A1 HK1256087 A1 HK 1256087A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- cells
- solid tumor
- tumor targeting
- bispecific car
- bispecific
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 210000001744 T-lymphocyte Anatomy 0.000 title 1
- 230000008685 targeting Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464403—Receptors for growth factors
- A61K39/464404—Epidermal growth factor receptors [EGFR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562202698P | 2015-08-07 | 2015-08-07 | |
PCT/US2016/045360 WO2017027291A1 (en) | 2015-08-07 | 2016-08-03 | Bispecific car t-cells for solid tumor targeting |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1256087A1 true HK1256087A1 (zh) | 2019-09-13 |
Family
ID=57984403
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK18115149.8A HK1256087A1 (zh) | 2015-08-07 | 2018-11-27 | 用於實體瘤靶向的雙特異性cart細胞 |
Country Status (9)
Country | Link |
---|---|
US (3) | US11458167B2 (zh) |
EP (1) | EP3331920A4 (zh) |
JP (2) | JP7162530B2 (zh) |
CN (1) | CN108174604B (zh) |
AU (2) | AU2016306209B2 (zh) |
CA (1) | CA2994829A1 (zh) |
HK (1) | HK1256087A1 (zh) |
MX (1) | MX2018001568A (zh) |
WO (1) | WO2017027291A1 (zh) |
Families Citing this family (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2015243922B2 (en) | 2014-04-10 | 2021-08-05 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Production of engineered T-cells by sleeping beauty transposon coupled with methotrexate selection |
MX2018001568A (es) | 2015-08-07 | 2019-04-25 | Seattle Children´S Hospital Dba Seattle Children´S Res Institute | Celulas t biespecificas de receptor quimerico de antigeno (car) para focalizacion a tumores solidos. |
KR20180105709A (ko) * | 2016-02-05 | 2018-09-28 | 시티 오브 호프 | 중추 신경계의 암의 치료를 위한 조작된 t 세포의 투여 |
WO2018026533A1 (en) | 2016-08-02 | 2018-02-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Monoclonal antibodies targeting glypican-2 (gpc2) and use thereof |
AU2017375630B2 (en) | 2016-12-12 | 2023-12-21 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells |
CN111212849A (zh) * | 2017-06-30 | 2020-05-29 | 纪念斯隆-凯特林癌症中心 | 用于癌症的过继性细胞疗法的组合物和方法 |
EP3645708A4 (en) * | 2017-06-30 | 2021-06-23 | Memorial Sloan-Kettering Cancer Center | COMPOSITIONS AND METHODS OF ADOPTIVE CELL THERAPIES AGAINST CANCER |
WO2019006468A1 (en) * | 2017-06-30 | 2019-01-03 | Memorial Sloan Kettering Cancer Center | COMPOSITIONS AND METHODS FOR ADOPTIVE CELL THERAPY |
CN111183156A (zh) * | 2017-07-31 | 2020-05-19 | 莱蒂恩技术公司 | 用于用抗cd19/cd20免疫治疗来治疗癌症的组合物和方法 |
CN109423495A (zh) * | 2017-08-24 | 2019-03-05 | 上海恒润达生生物科技有限公司 | 一种双靶向嵌合抗原受体及其用途 |
KR20200096758A (ko) | 2017-10-18 | 2020-08-13 | 인트렉손 코포레이션 | 스페이서를 포함하는 폴리펩타이드 조성물 |
MA50860A (fr) * | 2017-11-01 | 2020-09-09 | Juno Therapeutics Inc | Récepterus chimériques d'antigène contre l'antigène de maturation des cellules b et polynucleotides codants |
MA50855A (fr) * | 2017-11-01 | 2020-09-09 | Juno Therapeutics Inc | Procédé de génération de compositions thérapeutiques de cellules modifiées |
US11802163B2 (en) | 2017-11-10 | 2023-10-31 | The U.S.A., As Represented By The Secretary, Department Of Health And Human Services | Chimeric antigen receptors targeting glypican-3 or mesothelin |
US20210300986A1 (en) * | 2017-12-05 | 2021-09-30 | The Medical Research Infrastrutrure And Health Services Fund Of The Tel Aviv Medecal Center | T-cells comprising two different chimeric antigen receptors and uses thereof |
EP3720883B1 (en) | 2017-12-05 | 2023-04-19 | The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center | T-cells comprising anti-cd38 and anti-cd138 chimeric antigen receptors and uses thereof |
CN109970864A (zh) * | 2017-12-28 | 2019-07-05 | 上海细胞治疗研究院 | 一种双向激活共刺激分子受体及其用途 |
CN109970867B (zh) * | 2017-12-28 | 2022-10-18 | 上海细胞治疗研究院 | 一种cd40双向激活共刺激分子受体及其用途 |
CN109970866B (zh) * | 2017-12-28 | 2022-10-04 | 上海细胞治疗研究院 | 一种cd28双向激活共刺激分子受体及其用途 |
US10561686B2 (en) | 2018-01-12 | 2020-02-18 | Innovative Cellular Therapeutics CO., LTD. | Modified cell expansion and uses thereof |
WO2019140100A1 (en) * | 2018-01-11 | 2019-07-18 | Innovative Cellular Therapeutics Inc. | Modified cell expansion and uses thereof |
US10869888B2 (en) | 2018-04-17 | 2020-12-22 | Innovative Cellular Therapeutics CO., LTD. | Modified cell expansion and uses thereof |
GB201807862D0 (en) * | 2018-05-15 | 2018-06-27 | Ucl Business Plc | Chimeric antigen receptor |
US20210252058A1 (en) * | 2018-05-17 | 2021-08-19 | St. Jude Children's Research Hospital, Inc. | Chimeric antigen receptors with myd88 and cd40 costimulatory domains |
BR112020024292A2 (pt) | 2018-06-06 | 2021-03-02 | Massachusetts Institute Of Technology | rna circular para translação em células eucarióticas |
US11311603B2 (en) * | 2018-06-19 | 2022-04-26 | Nantcell, Inc. | HIV treatment compositions and methods |
KR20210031898A (ko) | 2018-07-13 | 2021-03-23 | 난징 레전드 바이오테크 씨오., 엘티디. | 전염병을 치료하기 위한 공동수용체 시스템 |
CN108948211B (zh) * | 2018-07-24 | 2021-08-20 | 北京美康基免生物科技有限公司 | 一种基于靶向gd2的嵌合抗原受体及其应用 |
EP3830112A4 (en) * | 2018-07-30 | 2022-12-21 | University of Southern California | IMPROVING THE EFFICIENCY AND SAFETY OF ADOPTIVE CELLULAR THERAPIES |
US12012463B2 (en) * | 2018-08-08 | 2024-06-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | High affinity monoclonal antibodies targeting glypican-2 and uses thereof |
CN110845621A (zh) * | 2018-08-21 | 2020-02-28 | 上海恒润达生生物科技有限公司 | 一种靶向egfr和cd19双靶点的嵌合抗原受体方法 |
CA3110926A1 (en) * | 2018-08-28 | 2020-03-05 | Pharos Vaccine Inc. | Improved lentiviral vector |
US20220348682A1 (en) | 2018-08-30 | 2022-11-03 | Innovative Cellular Therapeutics Holdings, Ltd. | Chimeric antigen receptor cells for treating solid tumor |
CN109503716B (zh) * | 2018-10-08 | 2021-04-27 | 浙江生研生物科技有限公司 | 一种双特异性嵌合抗原受体分子及其在肿瘤治疗上的应用 |
CN109266618B (zh) * | 2018-10-18 | 2021-04-23 | 赛元生物科技(杭州)有限公司 | 能够靶向肿瘤细胞的巨噬细胞及其制备方法 |
CN109400710A (zh) * | 2018-11-02 | 2019-03-01 | 山西大医院(山西医学科学院) | 一种靶向kif20a阳性胰腺癌双特异性抗体及其制备方法和应用 |
SG11202105238YA (en) * | 2018-11-19 | 2021-06-29 | Univ Texas | Suicide gene |
US10918667B2 (en) | 2018-11-20 | 2021-02-16 | Innovative Cellular Therapeutics CO., LTD. | Modified cell expressing therapeutic agent and uses thereof |
CA3121942A1 (en) * | 2018-12-14 | 2020-06-18 | Bluebird Bio, Inc. | Dimerizing agent regulated immunoreceptor complexes |
CN111748017A (zh) * | 2019-03-26 | 2020-10-09 | 上海瑞可新生物科技有限公司 | 一种抗原多肽及其表达载体、组合药物、试剂盒和应用 |
JP2022526856A (ja) * | 2019-04-12 | 2022-05-26 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 臨床的に意義のあるegfr変異型タンパク質との交差反応性を有する高親和性キメラ抗原受容体(car)を含む、組成物および方法 |
JP2022530773A (ja) * | 2019-04-30 | 2022-07-01 | アタラ バイオセラピューティクス,インコーポレーテッド | 抗原特異的cd19標的化car-t細胞 |
AU2020265679A1 (en) | 2019-04-30 | 2021-12-23 | Senti Biosciences, Inc. | Chimeric receptors and methods of use thereof |
WO2020227447A1 (en) * | 2019-05-07 | 2020-11-12 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric antigen receptors targeting glypican-2 |
CA3139032A1 (en) | 2019-05-22 | 2020-11-26 | Robert Alexander WESSELHOEFT | Circular rna compositions and methods |
EP3980453A4 (en) * | 2019-06-07 | 2023-07-05 | The Trustees of the University of Pennsylvania | T LYMPHOCYTES EXPRESSING DUAL CARS INDIVIDUALLY LINKED TO CD28 AND 4-1BB |
BR112022001688A2 (pt) * | 2019-07-30 | 2022-05-24 | Univ Health Network | Receptores de células t e métodos de uso dos mesmos |
CA3149543A1 (en) * | 2019-08-27 | 2021-03-04 | Donald M. O'rourke | Synthetic cars to treat il13r.alpha.2 positive human and canine tumors |
WO2021092560A1 (en) * | 2019-11-08 | 2021-05-14 | Humanigen, Inc. | Epha3 directed car-t cells for treatment of tumors |
ES2961245T3 (es) | 2019-12-04 | 2024-03-11 | Orna Therapeutics Inc | Composiciones y métodos de ARN circular |
CN113402612A (zh) | 2020-03-17 | 2021-09-17 | 西比曼生物科技(香港)有限公司 | 靶向cd19和cd20的联合嵌合抗原受体及其应用 |
EP3892720A1 (en) * | 2020-04-06 | 2021-10-13 | Innovative Cellular Therapeutics Holdings, Ltd. | Presenting cell and use thereof in cell therapy |
TW202208417A (zh) | 2020-05-05 | 2022-03-01 | 美商再生元醫藥公司 | 用於治療癌症之組合物及方法 |
WO2022036495A1 (en) | 2020-08-17 | 2022-02-24 | Utc Therapeutics Inc. | Lymphocytes-antigen presenting cells co-stimulators and uses thereof |
EP4259285A1 (en) * | 2020-12-09 | 2023-10-18 | Affyimmune Therapeutics, Inc. | Dual chimeric antigen receptor targeting epcam and icam-1 |
CN114685683A (zh) * | 2020-12-31 | 2022-07-01 | 博生吉医药科技(苏州)有限公司 | 靶向gd2的car-t细胞及其制备和应用 |
WO2023168436A1 (en) * | 2022-03-03 | 2023-09-07 | Board Of Regents, The University Of Texas System | Anti-cd19 and anti-cd79b chimeric antigen receptors and methods of use thereof |
CN114573711A (zh) * | 2022-03-04 | 2022-06-03 | 陕西师范大学 | 一种TanCAR的构建及其应用 |
CN114605560B (zh) * | 2022-03-30 | 2024-02-20 | 江苏蒙彼利生物科技有限公司 | 一种car-nk细胞及其制备方法与应用 |
WO2024026505A2 (en) * | 2022-07-29 | 2024-02-01 | Amit Patel | Disruption of telocyte activity |
WO2024059733A2 (en) * | 2022-09-14 | 2024-03-21 | Fred Hutchinson Cancer Center | Chimeric antigen receptors binding nectin-4 |
WO2024097911A1 (en) * | 2022-11-02 | 2024-05-10 | Fate Therapeutics, Inc. | Off-the-shelf therapeutic cells with multiplex genomic engineering for targeting gprc5d |
CN117338914A (zh) * | 2023-10-27 | 2024-01-05 | 中山市珈钰生物医药有限公司 | 一种同种异体树突细胞肿瘤疫苗及其制备方法和应用 |
Family Cites Families (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IE913929A1 (en) | 1990-11-13 | 1992-05-20 | Immunex Corp | Bifunctional selectable fusion genes |
US20020111474A1 (en) | 1990-12-14 | 2002-08-15 | Capon Daniel J. | Chimeric chains for receptor-associated signal transduction pathways |
JPH07507278A (ja) | 1992-06-01 | 1995-08-10 | ニューイングランド メディカル センター ホスピタルズ インク | Cd43キメラ分子による細胞間相互作用の阻害 |
US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
US5783186A (en) | 1995-12-05 | 1998-07-21 | Amgen Inc. | Antibody-induced apoptosis |
US6660257B1 (en) | 1996-10-25 | 2003-12-09 | Pharmacia Corporation | Circular permuteins of flt3 ligand |
US6410319B1 (en) | 1998-10-20 | 2002-06-25 | City Of Hope | CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies |
GB0015119D0 (en) | 2000-06-20 | 2000-08-09 | Angeletti P Ist Richerche Bio | Methods and means for regulation of gene expression |
AU2001270252B2 (en) | 2000-07-03 | 2007-02-08 | Catalent Pharma Solutions, Llc | Expression vectors |
DE60122765D1 (de) | 2000-11-07 | 2006-10-12 | Hope City | Cd19-spezifische umgezielte immunzellen |
BR0207854A (pt) | 2001-03-07 | 2004-08-24 | Merck Patent Gmbh | Tecnologia de expressão para proteìnas contendo uma porção de anticorpo de isotipo hìbrido |
US7070995B2 (en) | 2001-04-11 | 2006-07-04 | City Of Hope | CE7-specific redirected immune cells |
US20090257994A1 (en) | 2001-04-30 | 2009-10-15 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
WO2002097099A1 (en) | 2001-05-29 | 2002-12-05 | Valentis, Inc. | Regulated expression of ghrh |
US20050004017A1 (en) | 2001-09-18 | 2005-01-06 | Yuval Reiss | Methods and compositions for treating hcap associated diseases |
US20030148982A1 (en) | 2001-11-13 | 2003-08-07 | Brenner Malcolm K. | Bi-spcific chimeric T cells |
PL375033A1 (en) | 2002-04-11 | 2005-11-14 | Amgen, Inc. | Her-2 receptor tyrosine kinase molecules and uses thereof |
WO2004029284A2 (en) | 2002-09-30 | 2004-04-08 | Protein Design Labs, Inc. | Efficient generation of stable expression cell lines through the use of scorable homeostatic reporter genes |
US20040158329A1 (en) | 2003-02-10 | 2004-08-12 | Waldemar Link (Gmbh & Co.) | Hip joint prosthesis with shaft inserted into femur |
US7662387B2 (en) | 2003-02-20 | 2010-02-16 | Seattle Genetics | Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders |
US20050129671A1 (en) | 2003-03-11 | 2005-06-16 | City Of Hope | Mammalian antigen-presenting T cells and bi-specific T cells |
US20060160090A1 (en) | 2003-04-11 | 2006-07-20 | Macina Robert A | Composition splice variants and methods relating to cancer specific genes and proteins |
WO2005017102A2 (en) | 2003-05-30 | 2005-02-24 | Diadexus, Inc. | Compositions, splice variants and methods relating to ovarian specific nucleic acids and proteins |
AU2004261724B2 (en) | 2003-07-21 | 2010-06-17 | Msd Italia S.R.L. | Synthetic gene encoding human epidermal growth factor 2/neu antigen and uses thereof |
CA2543329A1 (en) | 2003-10-24 | 2005-05-06 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Orthogonal gene switches |
US20130266551A1 (en) | 2003-11-05 | 2013-10-10 | St. Jude Children's Research Hospital, Inc. | Chimeric receptors with 4-1bb stimulatory signaling domain |
US8071364B2 (en) | 2003-12-24 | 2011-12-06 | Transgenrx, Inc. | Gene therapy using transposon-based vectors |
US20090098142A1 (en) | 2004-06-09 | 2009-04-16 | Kasaian Marion T | Methods and compositions for treating and monitoring treatment of IL-13-associated disorders |
US7910101B2 (en) | 2004-10-25 | 2011-03-22 | Centocor, Inc. | Melanocortin receptor binding mimetibodies, compositions, methods and uses |
AU2006327175A1 (en) | 2005-12-21 | 2007-06-28 | Medimmune, Llc | Epha2 bite molecules and uses thereof |
CN101511994A (zh) | 2006-05-22 | 2009-08-19 | 海普罗塞尔有限公司 | 使用真核细胞系生成蛋白质 |
WO2008012237A1 (en) | 2006-07-24 | 2008-01-31 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Multi-antigen construct and uses thereof |
US7709253B2 (en) | 2006-08-04 | 2010-05-04 | The Board Of Trustees Of The Leland Stanford Junior University | Ligand-regulable transactivation systems, methods of use thereof, methods of detecting estrogen receptor ligands, and methods of differentiating estrogen receptor ligand agonists and antagonists |
CN101828113B (zh) | 2007-07-25 | 2014-04-16 | 德国弗劳恩霍夫协会债权安格万特学术研究所 | 自结合重组抗体融合蛋白 |
WO2009091826A2 (en) | 2008-01-14 | 2009-07-23 | The Board Of Regents Of The University Of Texas System | Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car) |
WO2009126789A2 (en) | 2008-04-09 | 2009-10-15 | Maxcyte, Inc. | Engineering and delivery of therapeutic compositions of freshly isolated cells |
HRP20211788T1 (hr) | 2008-08-26 | 2022-02-18 | City Of Hope | Postupak i pripravci za poboljšanje anti-tumorskog efektorskog funkcioniranja t stanica |
US8829173B2 (en) | 2008-09-26 | 2014-09-09 | Tocagen Inc. | Recombinant vectors |
CN102227503B (zh) | 2008-09-26 | 2015-10-21 | 托卡根公司 | 重组载体 |
US8329882B2 (en) | 2009-02-18 | 2012-12-11 | California Institute Of Technology | Genetic control of mammalian cells with synthetic RNA regulatory systems |
US20100332417A1 (en) | 2009-06-02 | 2010-12-30 | Targeted Molecular Diagnostics, Llc | Methods for the detection and quantitation of the p95 component of her2/neu (erbb2) |
US8075895B2 (en) | 2009-09-22 | 2011-12-13 | Janssen Pharmaceutica N.V. | Identification of antigenic peptides from multiple myeloma cells |
HUE044461T2 (hu) | 2009-11-03 | 2019-10-28 | Hope City | Csonkolt epidermális növekedési faktor receptor (EGFRT) transzdukált T-sejt szelekcióhoz |
JP5285678B2 (ja) | 2010-06-18 | 2013-09-11 | 株式会社エヌ・ティ・ティ・ドコモ | 移動通信方法及びコアネットワーク装置 |
DK2614077T3 (en) | 2010-09-08 | 2016-11-21 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Chimeric antigen receptors with an optimized hinge region |
AU2011338200B2 (en) | 2010-12-09 | 2017-02-23 | The Trustees Of The University Of Pennsylvania | Use of chimeric antigen receptor-modified T cells to treat cancer |
AU2012207356A1 (en) | 2011-01-18 | 2013-08-01 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treating cancer |
CN106074601A (zh) | 2011-03-23 | 2016-11-09 | 弗雷德哈钦森癌症研究中心 | 用于细胞免疫治疗的方法和组合物 |
JP2014514927A (ja) | 2011-04-13 | 2014-06-26 | イミュニカム・エイビイ | 抗原特異的t細胞の増殖のための方法 |
WO2012167192A2 (en) | 2011-06-01 | 2012-12-06 | Precision Biosciences, Inc. | Methods and products for producing engineered mammalian cell lines with amplified transgenes |
US20130011394A1 (en) | 2011-06-22 | 2013-01-10 | Hoffmann-La Roche Inc. | Complexes comprising mhc class i fusion polypeptides and antigen-specific antibodies and methods of use |
DE102011118018B4 (de) | 2011-10-25 | 2017-10-26 | Plasmidfactory Gmbh & Co. Kg | Minicircles mit Transpositionskassetten und ihre Verwendung zur Transformation von Zellen |
WO2013074916A1 (en) | 2011-11-18 | 2013-05-23 | Board Of Regents, The University Of Texas System | Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla |
ES2774160T3 (es) * | 2012-02-13 | 2020-07-17 | Seattle Childrens Hospital D/B/A Seattle Childrens Res Institute | Receptores de antígenos quiméricos biespecíficos y usos terapéuticos de los mismos |
ITRM20120058A1 (it) | 2012-02-20 | 2013-08-21 | Pisanelli Giovanni Codacci | Famiglia di molecole a base di zuccheri ad uso terapeutico e relativo procedimento di produzione |
EP3747898B1 (en) | 2012-02-22 | 2023-03-15 | The Trustees of the University of Pennsylvania | Use of icos-based cars to enhance antitumor activity and car persistence |
EA201990959A1 (ru) | 2012-04-11 | 2020-02-10 | Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез | Химерные антигенные рецепторы, нацеленные на антиген созревания b-клеток |
US20130280220A1 (en) | 2012-04-20 | 2013-10-24 | Nabil Ahmed | Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes |
WO2013177533A1 (en) | 2012-05-25 | 2013-11-28 | California Institute Of Technology | Expression of secreted and cell-surface polypeptides |
MX2014014650A (es) | 2012-05-30 | 2015-10-14 | Univ Washington | Minivectores superenrollados como una herramienta para la reparacion, alteración y reemplazo de ácido desoxirribonucleico. |
EP2669378A1 (en) | 2012-05-31 | 2013-12-04 | Helmut Hanenberg | Cytochrome P450 suicide gene system |
CN104350709B (zh) | 2012-06-01 | 2018-03-13 | 日本电气株式会社 | 交换机系统、线路卡、交换卡、fdb学习方法及fdb学习调停方法 |
RU2019126655A (ru) * | 2012-08-20 | 2019-11-12 | Фред Хатчинсон Кансэр Рисёч Сентер | Нуклеиновые кислоты, кодирующие химерные рецепторы, полипептидные химерные рецепторы, кодируемые ими, векторы экспрессии, содержащие их, выделенные клетки-хозяева, содержащие их, композиции, содержащие выделенные клетки-хозяева, а также способы получения выделенных клеток-хозяев in vitro, способы выбора нуклеиновых кислот, кодирующих химерные рецепторы, in vitro и способы проведения клеточной иммунотерапии у субъекта, имеющего опухоль |
WO2014039044A1 (en) | 2012-09-06 | 2014-03-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of producing t memory stem cell populations |
CN112430580A (zh) | 2012-10-02 | 2021-03-02 | 纪念斯隆-凯特琳癌症中心 | 用于免疫疗法的组合物和方法 |
US10117896B2 (en) * | 2012-10-05 | 2018-11-06 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
US20150329640A1 (en) | 2012-12-20 | 2015-11-19 | Bluebird Bio, Inc. | Chimeric antigen receptors and immune cells targeting b cell malignancies |
CN105339498A (zh) | 2013-03-07 | 2016-02-17 | 贝勒医学院 | 癌症中靶向cd138 |
EP2777711A1 (en) | 2013-03-11 | 2014-09-17 | Icon Genetics GmbH | Her2/Neu cancer vaccine |
UY35468A (es) | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
EP3004168A4 (en) | 2013-05-24 | 2017-03-01 | Board of Regents, The University of Texas System | Chimeric antigen receptor-targeting monoclonal antibodies |
NZ758715A (en) * | 2013-10-31 | 2023-01-27 | Seattle Children’S Hospital Dba Seattle Children’S Res Institute | Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof |
EP3858378A1 (en) | 2013-11-21 | 2021-08-04 | Autolus Limited | Cell |
CA2934436A1 (en) | 2013-12-20 | 2015-06-25 | Cellectis | Method of engineering multi-input signal sensitive t cell for immunotherapy |
CN107074957B (zh) * | 2014-01-13 | 2021-05-07 | 希望之城公司 | 在Fc间隔物区中具有突变的嵌合抗原受体(CAR)及其使用方法 |
RU2753965C2 (ru) | 2014-02-14 | 2021-08-24 | Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем | Химерные антигенные рецепторы и способы их получения |
ES2939760T3 (es) | 2014-03-15 | 2023-04-26 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico para antígenos |
AU2015243922B2 (en) | 2014-04-10 | 2021-08-05 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Production of engineered T-cells by sleeping beauty transposon coupled with methotrexate selection |
GB2541599B (en) | 2014-05-14 | 2020-05-20 | Carsgen Therapeutics Ltd | Nucleic acid for coding chimeric antigen receptor protein and T lymphocyte for expression of chimeric antigen receptor protein |
CA2951045A1 (en) | 2014-06-02 | 2015-12-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric antigen receptors targeting cd-19 |
TWI805109B (zh) | 2014-08-28 | 2023-06-11 | 美商奇諾治療有限公司 | 對cd19具專一性之抗體及嵌合抗原受體 |
EP3212223B1 (en) | 2014-10-27 | 2021-08-18 | Fred Hutchinson Cancer Research Center | Compositions and methods for boosting the efficacy of adoptive cellular immunotherapy |
GB201503742D0 (en) | 2015-03-05 | 2015-04-22 | Ucl Business Plc | Chimeric antigen receptor |
BR112017024757A2 (pt) | 2015-05-18 | 2018-11-13 | TCR2 Therapeutics Inc. | composições e métodos para reprogramação de tcr utilizando proteínas de fusão |
KR102526538B1 (ko) | 2015-06-10 | 2023-04-28 | 이뮤너티바이오, 인크. | 암을 치료하기 위한 변형된 nk-92 세포 |
EP3307877B1 (en) | 2015-06-12 | 2020-11-18 | Lentigen Technology, Inc. | Method to treat cancer with engineered t-cells |
MX2018001568A (es) | 2015-08-07 | 2019-04-25 | Seattle Children´S Hospital Dba Seattle Children´S Res Institute | Celulas t biespecificas de receptor quimerico de antigeno (car) para focalizacion a tumores solidos. |
KR20180105709A (ko) | 2016-02-05 | 2018-09-28 | 시티 오브 호프 | 중추 신경계의 암의 치료를 위한 조작된 t 세포의 투여 |
CN109415409B (zh) | 2016-04-01 | 2022-03-15 | 亘喜生物科技(上海)有限公司 | Flag标记的cd19-car-t细胞 |
TWI695010B (zh) | 2016-09-28 | 2020-06-01 | 美商凱特製藥公司 | 抗原結合分子類和使用彼等之方法 |
ES2811500T3 (es) | 2016-10-04 | 2021-03-12 | Prec Biosciences Inc | Dominios coestimuladores para su uso en células genéticamente modificadas |
AU2017375630B2 (en) | 2016-12-12 | 2023-12-21 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells |
JOP20180042A1 (ar) | 2017-04-24 | 2019-01-30 | Kite Pharma Inc | نطاقات ربط مولد ضد متوافقة مع البشر وطرق الاستخدام |
US10869888B2 (en) | 2018-04-17 | 2020-12-22 | Innovative Cellular Therapeutics CO., LTD. | Modified cell expansion and uses thereof |
US11104732B2 (en) | 2019-04-24 | 2021-08-31 | Innovative Cellular Therapeutics Holdings, Ltd. | Reducing immune inhibition induced by SIGLEC-15 |
-
2016
- 2016-08-03 MX MX2018001568A patent/MX2018001568A/es unknown
- 2016-08-03 US US15/750,708 patent/US11458167B2/en active Active
- 2016-08-03 JP JP2018506286A patent/JP7162530B2/ja active Active
- 2016-08-03 WO PCT/US2016/045360 patent/WO2017027291A1/en active Application Filing
- 2016-08-03 CA CA2994829A patent/CA2994829A1/en active Pending
- 2016-08-03 CN CN201680058143.5A patent/CN108174604B/zh active Active
- 2016-08-03 EP EP16835650.9A patent/EP3331920A4/en active Pending
- 2016-08-03 AU AU2016306209A patent/AU2016306209B2/en active Active
-
2018
- 2018-11-27 HK HK18115149.8A patent/HK1256087A1/zh unknown
-
2020
- 2020-11-03 US US17/088,005 patent/US11123369B2/en active Active
-
2022
- 2022-04-20 JP JP2022069615A patent/JP2022119759A/ja active Pending
- 2022-09-12 US US17/931,258 patent/US20230130938A1/en active Pending
-
2023
- 2023-10-05 AU AU2023241321A patent/AU2023241321A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP7162530B2 (ja) | 2022-10-28 |
AU2023241321A1 (en) | 2023-10-26 |
MX2018001568A (es) | 2019-04-25 |
US11123369B2 (en) | 2021-09-21 |
EP3331920A1 (en) | 2018-06-13 |
JP2018522567A (ja) | 2018-08-16 |
AU2016306209B2 (en) | 2023-07-06 |
WO2017027291A1 (en) | 2017-02-16 |
US20230130938A1 (en) | 2023-04-27 |
US20210085719A1 (en) | 2021-03-25 |
US20200215108A1 (en) | 2020-07-09 |
EP3331920A4 (en) | 2019-04-03 |
CN108174604A (zh) | 2018-06-15 |
AU2016306209A1 (en) | 2018-03-15 |
CN108174604B (zh) | 2023-06-23 |
CA2994829A1 (en) | 2017-02-16 |
US11458167B2 (en) | 2022-10-04 |
JP2022119759A (ja) | 2022-08-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1256087A1 (zh) | 用於實體瘤靶向的雙特異性cart細胞 | |
GB201621091D0 (en) | Convoy vehicle look-ahead | |
HK1250918A1 (zh) | 用於膠質母細胞瘤的egfr導向的car療法 | |
IL254700A0 (en) | Chimeric antigen receptor T-cells for the treatment of solid tumors expressing B.7-IZ.4 | |
PL3325323T3 (pl) | Pojazd szynowy | |
HK1245120A1 (zh) | 用於癌症的新治療 | |
GB2536002B (en) | Railway Vehicle Operation | |
HUE060564T2 (hu) | Jármû-architektúra | |
HUP1600666A1 (hu) | Szerkezeti elrendezés mozgó jármûvek mérlegelésére | |
GB2540634B (en) | Armoured vehicle | |
HK1250257A1 (zh) | 用於前列腺疾病的生物標記物組合 | |
ZA201605349B (en) | Width-adjustable heavy-goods vehicle | |
PL3280628T3 (pl) | Pojazd szynowy | |
KR102220409B9 (ko) | 차량용 범퍼 | |
GB201510496D0 (en) | Vehicle | |
GB201515879D0 (en) | Vehicle mounted shield | |
ZA201603482B (en) | Power supplies for vehicles | |
AU201614568S (en) | Car | |
TWD174465S (zh) | 汽車之部分 | |
AU363423S (en) | Car | |
AU363422S (en) | Car | |
AU5552P (en) | USEVO1201 Evolvulus hybrid | |
GB201516204D0 (en) | Vehicles | |
GB201515858D0 (en) | Hybrid car | |
GB201517081D0 (en) | Predicting increased risk for sporadic cancer |